Kiora Pharmaceuticals Partners with B2i Digital to Enhance Investor Engagement

Advancing Novel Therapies to Restore Vision in Retinal Diseases

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing novel therapeutics to treat ophthalmic diseases that lead to vision loss. Headquartered in Encinitas, California, Kiora is focused on inherited retinal diseases like retinitis pigmentosa, choroideremia, and Stargardt's disease, as well as posterior non-infectious uveitis.

The company's lead asset, KIO-301, is designed to restore vision in these diseases by reactivating surviving retinal cells. Kiora recently announced preliminary data from a Phase 1b study of KIO-301 in retinitis pigmentosa patients that showed promising signs of bioactivity and plans to report complete results in the fourth quarter of 2023.

With an estimated patient population exceeding 150,000 in the U.S., Kiora is targeting retinal diseases with high unmet needs and multi-billion dollar market potential. The company expects to report data from several clinical trials over the next two years as it advances its pipeline. Kiora is led by an experienced management team and board of directors with decades of ophthalmology drug development expertise.